Venous thrombosis in patients with giant cell arteritis: Features and outcomes in a cohort study

Joint Bone Spine

Volumn 84, Issue 3, 2017, Pages 323-326

  Ly, Kim Heang ^a   Liozon, Eric ^a   Dalmay, François ^b   Gondran, Guillaume ^a   Palat, Sylvain ^a   Bézanahary, Holy ^a   Lapébie, François Xavier ^a   Cypierre, Anne ^a   Nadalon, Sylvie ^a   Preux, Pierre Marie ^b   Fauchais, Anne Laure ^b  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

Author keywords

Giant cell arteritis; Glucocorticoids; Venous thrombosis

Indexed keywords

FLUINDIONE; HEPARIN; METHYLPREDNISOLONE; PREDNISONE; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BONE DISEASE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL LABORATORY; CLINICAL OUTCOME; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEATH; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; GIANT CELL ARTERITIS; HUMAN; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY RATE; MUSCULOSKELETAL DISEASE; MYOPATHY; NEUROMUSCULAR DISEASE; ONSET AGE; SIDE EFFECT; TIME TO TREATMENT; VEIN THROMBOSIS; COMPLICATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GIANT CELL ARTERITIS; HUMANS; MALE; VENOUS THROMBOSIS;

EID: 85008330468     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2016.04.011     Document Type: Article

References (20)

1. [1] Weyand, C.M., Goronzy, J.J., Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 371 (2014), 50–57.
2. [2] Liozon, E., Herrmann, F., Ly, K., et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 111 (2001), 211–217.
3. [3] Proven, A., Gabriel, S.E., Orces, C., et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49 (2003), 703–708.
4. [4] Zoller, B., Li, X., Sundquist, J., et al. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 379 (2012), 244–249.
5. [5] Avina-Zubieta, J.A., Bhole, V.M., Amiri, N., et al. The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study. Ann Rheum Dis 75 (2016), 148–154.
6. [6] Unizony, S., Menendez, M.E., Rastalsky, N., et al. Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency. Rheumatology (Oxford) 54 (2015), 1360–1368.
7. [7] Hunder, G.G., Bloch, D.A., Michel, B.A., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33 (1990), 1122–1128.
8. [8] Carruthers, E.C., Choi, H.K., Sayre, E.C., et al. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis 75 (2016), 110–116.
9. [9] Merkel, P.A., Lo, G.H., Holbrook, J.T., et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142 (2005), 620–626.
10. [10] Allenbach, Y., Seror, R., Pagnoux, C., et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome. Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 68 (2009), 564–567.
11. [11] Novikov, P., Makarov, E., Moiseev, S., et al. Venous thromboembolic events in systemic vasculitis. Ann Rheum Dis, 74, 2015, e27.
12. [12] Maradit Kremers, H., Reinalda, M.S., Crowson, C.S., et al. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 57 (2007), 279–286.
13. [13] Davis, J.M., Maradit Kremers, H., Crowson, C.S., et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56 (2007), 820–830.
14. [14] Calvo-Alen, J., Toloza, S.M., Fernandez, M., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis rheum 52 (2005), 2060–2068.
15. [15] Huerta, C., Johansson, S., Wallander, M.A., et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 167 (2007), 935–943.
16. [16] Johannesdottir, S.A., Horvath-Puho, E., Dekkers, O.M., et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 173 (2013), 743–752.
17. [17] Curtis, J.R., Westfall, A.O., Allison, J., et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55 (2006), 420–426.
18. [18] Brotman, D.J., Girod, J.P., Posch, A., et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 118 (2006), 247–252.
19. [19] Van Zaane, B., Nur, E., Squizzato, A., et al. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 94 (2009), 2743–2750.
20. [20] Baslund, B., Helleberg, M., Faurschou, M., et al. Mortality in patients with giant cell arteritis. Rheumatology 54 (2015), 139–143.